Biogen

Resources for Professionals

LuMind IDSC Statement on FDA Approval of Leqembi

Last week the FDA announced a full approval of a new drug called Leqembi to…

Kim WarrenJuly 13, 2023

Health and Research – Alzheimer's/Dementia Resources for Professionals

Alzheimer’s Disease Research Focus: Updates on Current and Upcoming Clinical Trials

During this presentation, Dr. Jim Hendrix will discuss the recent research progress in Down syndrome…

Rigsby RigsbyApril 22, 2022

Health and Research – Alzheimer's/Dementia

The State of Alzheimer’s Research, with Dr Marcia Ratner & Dr James Hendrix

Dr. Marcia Ratner & Dr. James Hendrix discuss recent developments in Alzheimer’s research.Source: Dr. Marcia…

Rigsby RigsbyDecember 3, 2021

Health and Research – Alzheimer's/Dementia

Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs

This blogpost from a former FDA insider on the power of the patient helps us…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab

On October 22, 2019, the biopharmaceutical company, Biogen, announced that they will be going to…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

LuMind IDSC signs on to NTG statement re: Aduhelm

“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage

LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003

Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

Progress in Alzheimer’s Disease Builds Renewed Interest in Research

In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer’s Disease

The NTG brought together a national panel of expert researchers and practitioners in the field…

Rigsby RigsbyOctober 20, 2021

LuMind IDSC Statement on FDA Approval of Leqembi

The State of Alzheimer’s Research, with Dr Marcia Ratner & Dr James Hendrix

Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs

Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab

LuMind IDSC signs on to NTG statement re: Aduhelm

LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage

FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003

Progress in Alzheimer’s Disease Builds Renewed Interest in Research

Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer’s Disease

CONTACT LUMIND IDSC

QUICK LINKS

JOIN US